Document is current
Any future updates will be listed below
-
Authors
Watanabe, Akira https://orcid.org/0000-0003-0496-5945
Kitano, Sae https://orcid.org/0009-0008-6896-3088
Kato, Chikage
Tsunashima, Ryo https://orcid.org/0000-0003-2663-0142
Matsui, Chise
Matsumoto, Saya
Omatsu, Ikoi
Konishi, Eiichi
Sota, Yoshiaki https://orcid.org/0000-0001-5963-652X
Shiraishi, Takumi https://orcid.org/0000-0001-8529-8915
Okumi, Masayoshi https://orcid.org/0000-0001-7443-2621
Morita, Midori https://orcid.org/0000-0003-4083-4432
Sakaguchi, Koichi
Ukimura, Osamu https://orcid.org/0000-0003-3443-3210
Naoi, Yasuto https://orcid.org/0000-0002-6090-0137
- License Information
-
More Information
Article History
Received: 28 February 2025
Accepted: 13 September 2025
First Online: 25 September 2025
Declarations
:
: Yasuto Naoi has received research funding from Sysmex, ONO, Daiichi-Sankyo and AstraZeneca, and honoraria from AstraZeneca, Pfizer, Eli Lilly, ONO, Daiichi-Sankyo and Chugai outside the submitted work; he holds joint patents with Sysmex including Curebest™ 95GC Breast (JP.5725274.B2). Osamu Ukimura and Takumi Shiraishi are the patent inventor of the tissue-dividing device. The other authors declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Kyoto Prefectural University of Medicine Ethics Committee (ERB-C-2415-1).
: Informed consent was obtained from all individual participants included in the study.
